Covaxin is an inactivated vaccine, administered in two doses with an interval of four weeks. The vaccine has an efficacy rate of 81%, as per the preliminary data from its phase 3 trial.
Covishield is a virus vector vaccine, also administered in two doses with an interval of 8 weeks. International clinical trials of the Oxford-AstraZeneca vaccine showed that when people were given a half dose and then a full dose, effectiveness hit 90%.